(CRBN) Corbion - Ratings and Ratios
Lactic Acid, Food Preservation, Algae Ingredients, Bioplastics, Functional Blends
Dividends
| Dividend Yield | 3.34% |
| Yield on Cost 5y | 1.63% |
| Yield CAGR 5y | 6.11% |
| Payout Consistency | 89.6% |
| Payout Ratio | 57.1% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 36.6% |
| Value at Risk 5%th | 48.3% |
| Relative Tail Risk | -19.77% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.51 |
| Alpha | -18.18 |
| CAGR/Max DD | -0.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.587 |
| Beta | 0.237 |
| Beta Downside | 0.265 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.91% |
| Mean DD | 39.33% |
| Median DD | 43.01% |
Description: CRBN Corbion November 16, 2025
Corbion N.V. (AS: CRBN) is a Dutch specialty-chemicals company that manufactures lactic-acid-based ingredients, food-preservation solutions, functional blends and algae-derived products. It serves a global customer base across food, home-care, personal-care, animal nutrition, pharma, medical-device and bioplastics markets, operating through two reporting segments: Functional Ingredients & Solutions and Health & Nutrition.
Key quantitative signals (as of FY 2023) include €1.6 bn of revenue, a 4.5 % EBITDA margin and a 12 % year-over-year increase in sales of its bioplastic and algae-oil lines, driven by rising demand for sustainable packaging and alternative omega-3 sources. The sector’s base-rate growth is roughly 6–8 % CAGR for bio-based chemicals, while regulatory trends in the EU and North America (e.g., stricter food-preservative standards) provide a tailwind for Corbion’s “clean-label” positioning. A material risk is the company’s exposure to volatile raw-material costs (e.g., corn and sugar feedstocks), which could compress margins if not offset by price pass-through.
If you want a deeper, data-rich assessment of Corbion’s valuation dynamics, the ValueRay platform offers a transparent, model-driven analysis that can help you test these assumptions and explore scenario outcomes.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (111.1m TTM) > 0 and > 6% of Revenue (6% = 132.9m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA 5.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.11% (prev 1.67%; Δ 2.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 226.3m > Net Income 111.1m (YES >=105%, WARN >=100%) |
| Net Debt (404.9m) to EBITDA (300.7m) ratio: 1.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.1m) change vs 12m ago -2.77% (target <= -2.0% for YES) |
| Gross Margin 23.54% (prev 22.70%; Δ 0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 139.4% (prev 72.11%; Δ 67.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.47 (EBITDA TTM 300.7m / Interest Expense TTM 45.7m) >= 6 (WARN >= 3) |
Altman Z'' 3.80
| (A) 0.06 = (Total Current Assets 514.2m - Total Current Liabilities 423.3m) / Total Assets 1.45b |
| (B) 0.47 = Retained Earnings (Balance) 685.1m / Total Assets 1.45b |
| (C) 0.13 = EBIT TTM 204.2m / Avg Total Assets 1.59b |
| (D) 0.94 = Book Value of Equity 685.1m / Total Liabilities 727.3m |
| Total Rating: 3.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.98
| 1. Piotroski 6.0pt |
| 2. FCF Yield -4.82% |
| 3. FCF Margin -3.35% |
| 4. Debt/Equity 0.61 |
| 5. Debt/Ebitda 1.35 |
| 6. ROIC - WACC (= 9.76)% |
| 7. RoE 15.36% |
| 8. Rev. Trend 71.19% |
| 9. EPS Trend -34.60% |
What is the price of CRBN shares?
Over the past week, the price has changed by +5.51%, over one month by +8.56%, over three months by +13.31% and over the past year by -10.13%.
Is CRBN a buy, sell or hold?
What are the forecasts/targets for the CRBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.3 | 21.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 19.2 | 0.1% |
CRBN Fundamental Data Overview November 27, 2025
Market Cap EUR = 1.13b (1.13b EUR * 1.0 EUR.EUR)
P/E Trailing = 17.5586
P/E Forward = 12.7877
P/S = 0.8738
P/B = 1.4393
Beta = 1.038
Revenue TTM = 2.21b EUR
EBIT TTM = 204.2m EUR
EBITDA TTM = 300.7m EUR
Long Term Debt = 244.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 200.2m EUR (from shortLongTermDebt, last quarter)
Debt = 445.0m EUR (Calculated: Short Term 200.2m + Long Term 244.8m)
Net Debt = 404.9m EUR (from netDebt column, last quarter)
Enterprise Value = 1.54b EUR (1.13b + Debt 445.0m - CCE 40.1m)
Interest Coverage Ratio = 4.47 (Ebit TTM 204.2m / Interest Expense TTM 45.7m)
FCF Yield = -4.82% (FCF TTM -74.1m / Enterprise Value 1.54b)
FCF Margin = -3.35% (FCF TTM -74.1m / Revenue TTM 2.21b)
Net Margin = 5.02% (Net Income TTM 111.1m / Revenue TTM 2.21b)
Gross Margin = 23.54% ((Revenue TTM 2.21b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 25.56% (prev 23.35%)
Tobins Q-Ratio = 1.06 (Enterprise Value 1.54b / Total Assets 1.45b)
Interest Expense / Debt = 4.92% (Interest Expense 21.9m / Debt 445.0m)
Taxrate = 2.64% (1.20m / 45.4m)
NOPAT = 198.9m (EBIT 204.2m * (1 - 2.64%))
Current Ratio = 1.21 (Total Current Assets 514.2m / Total Current Liabilities 423.3m)
Debt / Equity = 0.61 (Debt 445.0m / totalStockholderEquity, last quarter 726.2m)
Debt / EBITDA = 1.35 (Net Debt 404.9m / EBITDA 300.7m)
Debt / FCF = -5.46 (negative FCF - burning cash) (Net Debt 404.9m / FCF TTM -74.1m)
Total Stockholder Equity = 723.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.64% (Net Income 111.1m / Total Assets 1.45b)
RoE = 15.36% (Net Income TTM 111.1m / Total Stockholder Equity 723.2m)
RoCE = 21.10% (EBIT 204.2m / Capital Employed (Equity 723.2m + L.T.Debt 244.8m))
RoIC = 16.06% (NOPAT 198.9m / Invested Capital 1.24b)
WACC = 6.30% (E(1.13b)/V(1.58b) * Re(6.89%) + D(445.0m)/V(1.58b) * Rd(4.92%) * (1-Tc(0.03)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.80%
Fair Price DCF = unknown (Cash Flow -74.1m)
EPS Correlation: -34.60 | EPS CAGR: -45.43% | SUE: 0.0 | # QB: 0
Revenue Correlation: 71.19 | Revenue CAGR: 19.49% | SUE: -0.06 | # QB: 0
EPS next Year (2026-12-31): EPS=1.44 | Chg30d=-0.010 | Revisions Net=-3 | Growth EPS=+9.4% | Growth Revenue=+1.2%